查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1552627

抗精神病药物市场规模、份额、趋势分析报告：按疾病、药物、治疗药物类别、分销管道、地区、细分市场预测，2024-2030

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

抗精神病药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球抗精神病药物市场规模将达到249.7亿美元，2024年至2030年复合年增长率为6.1%。

不断开发更好的下一代产品以克服现有产品的副作用和不良反应，正在创造对新产品的需求。预计这将推动市场。

抗精神病药物的快速成长是由于精神病和其他精神障碍的盛行率上升。各国政府正致力于提高人们对心理健康和精神疾病的意识提升，预计将进一步推动抗精神病药物的需求。政府机构正在与大公司合作实施社会计划，以消除社会上与精神障碍相关的耻辱。

抗精神病药物的副作用，如失眠、口干、嗜睡和视力模糊，预计会降低患者的接受程度，进而影响生长。此外，潜在的依赖性、习惯形成和成瘾也影响了这些药物的采用。

Zyprexa于 2011 年 10 月失去专利保护，Seroquel和Risperdal于 2012 年失去专利保护，阻碍了这些药物的市场成长。学名药的进入也减缓了现有品牌的成长。

抗精神病药物市场报告亮点

  • 2023年，思觉失调症将占最大的市场收益占有率，达到39.2%。思觉失调症是一种严重的精神疾病，影响着世界各地的许多人。
  • Aripiprazole在 2023 年占最大的市场销售份额。由于采用第三代产品，该细分市场的销售额将会增加。此外，预计产品核可在预测期内将出现最高成长。
  • 预计 Brexpiprmaze 在预测期内的复合年增长率将达到 9.8%，是最快的。
  • 2023年，第二代治疗类别占最大的市场收益占有率，达62.9%。该细分市场的成长归因于市场上存在许多第二代药物，例如 Hafila、Invega、 Seroquel XR 和Zyprexa。
  • 零售药局领域主导市场，并在 2023 年占据最大份额。零售药局对于患者来说很方便，通常是需要处方药的患者的第一个接触点。
  • 北美市场占据主导地位，2023 年收益占有率为 37.67%。促成该地区市场主导地位的重要因素包括该地区精神障碍的严重流行以及着名生物製药公司的市场影响。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章抗精神病药物市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗精神病药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章抗精神病药物市场：依疾病分类的估计与趋势分析

  • 细分仪表板
  • 抗精神病药物市场：2023年及2030年疾病变化分析
  • 思觉失调症
  • 躁郁症
  • 单相情感障碍
  • 失智
  • 其他的

第五章抗精神病药物市场：按药物估计和趋势分析

  • 细分仪表板
  • 抗精神病药物市场：2023年及2030年药物波动分析
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • 帕潘立酮棕榈酸酯
  • 其他的

第六章 抗精神病药物市场：依治疗药物类别估计与趋势分析

  • 细分仪表板
  • 抗精神病药物市场：2023年和2030年治疗药物类别的波动分析
  • 第一代
  • 第二代
  • 第三代

第七章抗精神病药物市场：按分销管道的估计和趋势分析

  • 细分仪表板
  • 抗精神病药物市场：2023 年和 2030 年分销管道变化分析
  • 医院药房
  • 零售药房
  • 网路药房

第八章抗精神病药物市场：区域估计和趋势分析

  • 2023 年和 2030 年抗精神病药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • H.Lundbeck A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Janssen Global Services, LLC
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Sumitomo Pharma
    • Alkermes
    • Bristol-Myers Squibb Company
简介目录
Product Code: GVR-1-68038-408-6

Antipsychotic Drugs Market Growth & Trends:

The global antipsychotic drugs market size is expected to reach USD 24.97 billion by 2030, growing at CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. This factor is anticipated to propel the market.

Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.

Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.

Established brands such as, Zyprexa lost patent protection in October 2011, followed by Seroquel and Risperdal in 2012, which hampers the market growth for these drugs. Also, the entry of generic versions of these products slowed the growth of the already existing brands.

Antipsychotic Drugs Market Report Highlights:

  • Schizophrenia accounted for the largest market revenue share of 39.2% in 2023. Schizophrenia is a serious mental illness that impacts a significant amount of individuals worldwide.
  • Aripiprazole accounted for the largest market revenue share in 2023. The sales of this segment increase with the adoption of third-generation products. Furthermore, it is anticipated that product approvals are expected to experience the most significant growth during the projected period.
  • Brexpiprazole is expected to register the fastest CAGR of 9.8% during the forecast period.
  • The second generation therapeutic class accounted for the largest market revenue share of 62.9% in 2023. The growth of this segment can be attributed to the presence of a number of second-generation medications available in the market, such as HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, and others.
  • The retail pharmacies segment dominated the market and accounted for the largest share in 2023. Retail pharmacies are easily available to patients, and they often act as the initial point of contact for individuals in need of prescription medications.
  • North America dominated the market with revenue share of 37.67% in 2023. Some of the critical factors attributable to the region's market dominance include the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Antipsychotic Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Antipsychotic Drugs Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Schizophrenia
    • 4.3.1. Schizophrenia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Bipolar Disorder
    • 4.4.1. Bipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Unipolar Disorder
    • 4.5.1. Unipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dementia
    • 4.6.1. Dementia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Antipsychotic Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Risperidone
    • 5.3.1. Risperidone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Quetiapine
    • 5.4.1. Quetiapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Olanzapine
    • 5.5.1. Olanzapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Aripiprazole
    • 5.6.1. Aripiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Brexpiprazole
    • 5.7.1. Brexpiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Paliperidone Palmitate
    • 5.8.1. Paliperidone Palmitate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. First Generation
    • 6.3.1. First Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Second Generation
    • 6.4.1. Second Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Third Generation
    • 6.5.1. Third Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Antipsychotic Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. U.K.
      • 8.3.2.1. U.K. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. China
      • 8.4.2.1. China Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Japan Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. UAE
      • 8.6.3.1. UAE Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. South Africa
      • 8.6.4.1. South Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. H.Lundbeck A/S
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Otsuka Pharmaceutical Co., Ltd.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. Janssen Global Services, LLC
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. AbbVie, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Teva Pharmaceutical Industries Ltd.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Dr. Reddy's Laboratories Ltd.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Sumitomo Pharma
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Alkermes
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives